Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Psyence Biomedical ( (PBM) ) is now available.
Psyence Biomedical Ltd. announced a leadership change on October 9, 2025, with Dr. Neil Maresky transitioning from CEO to Global Head of Clinical Development, focusing on global clinical initiatives. Jody Aufrichtig, the company’s Chairman, has taken over as CEO to manage Nasdaq-related and corporate operations, with plans to fill the board vacancy at the next shareholder meeting.
More about Psyence Biomedical
Psyence Biomedical Ltd. operates in the biomedical industry, focusing on clinical development initiatives. The company is engaged in conducting clinical trials, including a Phase 2b trial in Australia, and is involved in Nasdaq-related operations.
Average Trading Volume: 2,107,099
Technical Sentiment Signal: Sell
Current Market Cap: $2.53M
See more data about PBM stock on TipRanks’ Stock Analysis page.